DekaBank Deutsche Girozentrale Sells 76,000 Shares of Indivior PLC (NASDAQ:INDV)

DekaBank Deutsche Girozentrale reduced its stake in Indivior PLC (NASDAQ:INDV) by 62.4% during the 4th quarter, Holdings Channel reports. The fund owned 45,766 shares of the company’s stock after selling 76,000 shares during the period. DekaBank Deutsche Girozentrale’s holdings in Indivior were worth $692,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Wells Fargo & Company MN bought a new position in Indivior in the 2nd quarter valued at about $34,000. Qube Research & Technologies Ltd acquired a new position in shares of Indivior during the 3rd quarter worth approximately $41,000. Legal & General Group Plc acquired a new position in shares of Indivior during the 3rd quarter worth approximately $109,000. Alliancebernstein L.P. acquired a new position in shares of Indivior during the 2nd quarter worth approximately $310,000. Finally, Campbell & CO Investment Adviser LLC acquired a new position in shares of Indivior during the 3rd quarter worth approximately $801,000. 60.33% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Separately, Craig Hallum started coverage on shares of Indivior in a research report on Wednesday, April 3rd. They set a “buy” rating and a $37.00 target price on the stock.

Indivior Trading Up 2.2 %

NASDAQ INDV opened at $19.74 on Tuesday. The firm has a market capitalization of $2.72 billion, a price-to-earnings ratio of -986.51 and a beta of 0.46. The firm’s 50 day simple moving average is $20.35 and its 200 day simple moving average is $18.44. Indivior PLC has a 1 year low of $14.38 and a 1 year high of $26.50.

Indivior (NASDAQ:INDV) last posted its quarterly earnings results on Thursday, February 22nd. The company reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.28 by $0.15. The business had revenue of $293.00 million for the quarter, compared to analyst estimates of $260.00 million. Indivior had a net margin of 0.18% and a return on equity of 538.18%. On average, equities research analysts forecast that Indivior PLC will post 2.03 earnings per share for the current year.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.